期刊
JOURNAL OF NEUROCHEMISTRY
卷 154, 期 6, 页码 CP5-597出版社
WILEY
DOI: 10.1111/jnc.15007
关键词
Alzheimer's disease; amyloid beta-protein; long-term depression; long-term potentiation; soluble A beta oligomers; synaptic plasticity
资金
- Foundation for the National Institutes of Health [AG 027443, AG 036694]
It is increasingly accepted that early cognitive impairment in Alzheimer's disease results in considerable part from synaptic dysfunction caused by the accumulation of a range of oligomeric assemblies of amyloid beta-protein (A beta). Most studies have used synthetic A beta peptides to explore the mechanisms of memory deficits in rodent models, but recent work suggests that A beta assemblies isolated from human (AD) brain tissue are far more potent and disease-relevant. Although reductionist experiments show A beta oligomers to impair synaptic plasticity and neuronal viability, the responsible mechanisms are only partly understood. Glutamatergic receptors, GABAergic receptors, nicotinic receptors, insulin receptors, the cellular prion protein, inflammatory mediators, and diverse signaling pathways have all been suggested. Studies using AD brain-derived soluble A beta oligomers suggest that only certain bioactive forms (principally small, diffusible oligomers) can disrupt synaptic plasticity, including by binding to plasma membranes and changing excitatory-inhibitory balance, perturbing mGluR, PrP, and other neuronal surface proteins, down-regulating glutamate transporters, causing glutamate spillover, and activating extrasynaptic GluN2B-containing NMDA receptors. We synthesize these emerging data into a mechanistic hypothesis for synaptic failure in Alzheimer's disease that can be modified as new knowledge is added and specific therapeutics are developed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据